fbpx

molecules of the month

vimseltinib

selective CSF1R kinase inhibitor

oral, 30 mg BIW, phase III, cancer

from structure-based design

Molecular Cancer Therapeutics

Deciphera Pharmaceuticals

Chemical structure of molecule Vimseltinib (DCC-3014)
1 min read

The Deciphera CSF1R kinase inhibitor, vimseltinib (DCC-3014), is a selective oral TKI that induces an inactive conformation of CSF1R by biomimetically nucleating an array of 17 H-bonds in the switch control region of this switch control kinase. Several small and large molecule agents targeting CSF1R have been in development, and a small molecule CSF1R inhibitor (pexidartinib) was approved in 2019. Vimseltinib significantly inhibited CSF1R signaling in PK/PD models at doses as low as 3 mg/kg orally and depletes macrophages in efficacy models. Single agent and combination efficacy with anti-PD1 immunotherapy in a syngeneic mouse colorectal cancer model with effects on the adaptive immune system were also observed, in agreement with the hypothesis that certain macrophages play a role in tumor immune evasion. In…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: